ADME of monoclonal antibody biotherapeutics: Knowledge gaps and emerging tools

Bioanalysis

Volumn 5, Issue 16, 2013, Pages 2003-2014

  Lee, Jean W ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; CYTOCHROME P450; FC RECEPTOR; FLUORESCENT DYE; INDIUM 111; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PACLITAXEL; RITUXIMAB; SIMVASTATIN; TOCILIZUMAB; TRASTUZUMAB; ZIRCONIUM;

ALLOMETRY; ANALYTIC METHOD; AREA UNDER THE CURVE; AUTORADIOGRAPHY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RECEPTOR BINDING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECIES DIFFERENCE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VASCULAR TISSUE;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS;

EID: 84882258505     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.144     Document Type: Review

References (99)

1. Dimasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: Success rates for investigational drugs. Clin. Pharmacol. Therap. 87(3), 272-277 (2010
2. Xu X, Vugmeyster Y. Challenges and Opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. AAPS J. 14(4), 781-791 (2012
3. Deleu D, Alsharoqi I, Al Jumah MA et al. Will new injection devices for interferon beta-1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East. Intl J. Neurosci. 121(4), 171-175 (2011
4. Mccoy EK, Wright BM. A review of insulin pen devices. Postgraduate Medicine 122(3), 81-88 (2010
5. Lin JH. Pharmacokinetics of biotech drugs: Peptides, proteins and monoclonal antibodies. Curr. Drug Metab. 10(7), 661-691 (2009
6. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93(11), 2645-2668 (2004
7. Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 14(3), 559-570 (2012
8. Porter CJ, Edwards GA, Charman SA. Lymphatic transport of proteins after s.c. injection: Implications of animal model selection. Adv. Drug Deliv. Rev. 50(1-2), 157-171 (2001
9. Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci. 89(3), 297-310 (2000
10. Wang W, Chen N, Shen X et al. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab. Dispos. 40(5), 952-962 (2012
11. Boswell CA, Bumbaca D, Fielder PJ, Khawli LA. Compartmental tissue distribution of antibody therapeutics: Experimental approaches and interpretations. AAPS J. 14(3), 612-618 (2012
12. Close DM, Xu T, Sayler GS, Ripp S. In vivo bioluminescent imaging (BLI): Noninvasive visualization and interrogation of biological processes in living animals. Sensors 11(1), 180-206 (2011
13. Hoppin J, Orcutt KD, Hesterman JY et al. Assessing antibody pharmacokinetics in mice with in vivo imaging. J. Pharmacol. Exp. Therap. 337(2), 350-358 (2011
14. Oeste CL, Seco E, Patton WF, Boya P, Perez-Sala D. Interactions between autophagic and endo-lysosomal markers in endothelial cells. Histochemistry Cell Biol. 139(5), 659-670 (2012
15. Romer T, Leonhardt H, Rothbauer U. Engineering antibodies and proteins for molecular in vivo imaging. Curr. Opin. Biotechnol. 22(6), 882-887 (2011
16. Kagan L, Turner MR, Balu-Iyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies: Role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharmaceut. Res. 29(2), 490-499 (2012
17. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinetics 49(8), 493-507 (2010
18. Jain RK. Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression and function. J. Control. Rel. 74(1-3), 7-25 (2001
19. Castellino S. MALDI imaging MS analysis of drug distribution in tissue: The right time!(?). Bioanalysis 4(21), 2549-2551 (2012
20. Morgan P, Van Der Graaf PH, Arrowsmith J et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17(9-10), 419-424 (2012
21. Duan X, Abuqayyas L, Dai L, Balthasar JP, Qu J. High-throughput method development for sensitive, accurate, and reproducible quantification of therapeutic monoclonal antibodies in tissues using orthogonal array optimization and nano liquid chromatography/ selected reaction monitoring mass spectrometry. Anal. Chem. 84(10), 4373-4382 (2012
22. Deutskens F, Yang J, Caprioli RM. High spatial resolution imaging mass spectrometry and classical histology on a single tissue section. J. Mass Spectrom. 46(6), 568-571 (2011
23. Goodwin RJ, Pennington SR, Pitt AR: Protein and peptides in pictures: Imaging with MALDI mass spectrometry. Proteomics 8(18), 3785-3800 (2008
24. Frei AP, Jeon OY, Kilcher S et al. Direct identification of ligand-receptor interactions on living cells and tissues. Nat. Biotechnol. 30(10), 997-1001 (2012
25. Herzog F, Kahraman A, Boehringer D et al. Structural probing of a protein phosphatase 2A network by chemical cross-linking and mass spectrometry. Science 337(6100), 1348-1352 (2012
26. Wyant T, Lackey A, Green M. Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist. J. Transl. Med. 6, 76 (2008
27. Bendall SC, Simonds EF, Qiu P et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332(6030), 687-696 (2011
28. Nolan GP. Flow cytometry in the post fluorescence era. Best Practice Res. Clin. Haematol. 24(4), 505-508 (2011
29. Roopenian DC, Akilesh S. FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7(9), 715-725 (2007
30. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Exp. Opin. Biol. Ther. 5(Suppl. 1), S37-47 (2005
31. Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int. Immunol. 15(2), 187-195 (2003
32. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thrombosis Haem. 88(6), 898-899 (2002
33. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn. Immunol. 89(4), 573-578 (1996
34. Kim J, Bronson CL, Wani MA et al. Beta 2-microglobulin deficient mice catabolize IgG more rapidly than FcRn- alpha-chain deficient mice. Exp. Biol. Med. 233(5), 603-609 (2008
35. Wani MA, Haynes LD, Kim J et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc. Natl Acad. Sci. USA 103(13), 5084-5089 (2006
36. Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J. Immunol. 158(5), 2211-2217 (1997
37. Vaughn DE, Milburn CM, Penny DM, Martin WL, Johnson JL, Bjorkman PJ. Identification of critical IgG binding epitopes on the neonatal Fc receptor. J. Mol. Biol. 274(4), 597-607 (1997
38. Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: From bench to bedside. Br. J. Haematol. 1365-2141 (2010
39. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174(6), 1483-1489 (1991
40. Dall'acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281(33), 23514-23524 (2006
41. Hinton PR, Johlfs MG, Xiong JM et al. Engineered human IgG antibodies with longer serum half-lives in primates. The Journal of biological chemistry 279(8), 6213-6216 (2004
42. Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, Morrison SL. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol. Immunol. 43(9), 1462-1473 (2006
43. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. mAbs 3(5), 422-430 (2011
44. Kanda Y, Yamada T, Mori K et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 17(1), 104-118 (2007
45. Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: What are the pharmacokinetic and pharmacodynamic considerations for drug development? Exp. Opin. Drug Metab. Toxicol. 8(2), 141-160 (2012
46. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 11(1-2), 81-88 (2006
47. Wang W, Lu P, Fang Y et al. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab. Dispos. 39(9), 1469-1477 (2011
48. Adler M, Wacker R, Niemeyer CM. Sensitivity by combination: Immuno-PCR and related technologies. Analyst 133(6), 702-718 (2008
49. Hall MP, Gegg C, Walker K et al. Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: Strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J. 12(4), 576-585 (2010
50. Hager T, Spah C, Xu J, Salimi-Moosavi H, Hall M. Differential ELISA and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: Application to various FGF21 modalities. Anal. Chem. (2013
51. Hecht R, Li YS, Sun J et al. Rationale-based engineering of a potent long-acting fgf21 analog for the treatment of Type 2 diabetes. PloS One 7(11), e49345 (2012
52. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann. NY Acad. Sci. 1253, 170-180 (2012
53. Cooper HJ, Hakansson K, Marshall AG. The role of electron capture dissociation in biomolecular analysis. Mass Spectrom. Rev. 24(2), 201-222 (2005
54. Zhang Z, Shah B. Prediction of collision-induced dissociation spectra of common N-glycopeptides for glycoform identification. Anal. Chem. 82(24), 10194-10202 (2010
55. Branten AJ, Du Buf-Vereijken PW, Klasen IS et al. Urinary excretion of beta2- microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: A validation study. J. Am. Soc. Nephrol. 16(1), 169-174 (2005
56. Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Therap. 288(1), 371-378 (1999
57. Mahmood I. Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J. Pharm. Sci. 98(10), 3850-3861 (2009
58. Rehlaender BN, Cho MJ. Antibodies as carrier proteins. Pharm. Res. 15(11), 1652-1656 (1998
59. Bazin-Redureau M, Pepin S, Hong G, Debray M, Scherrmann JM. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol. Appl. Pharmacol. 150(2), 295-300 (1998
60. Grene-Lerouge NA, Bazin-Redureau MI, Debray M, Scherrmann JM. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol. Appl. Pharmacol. 138(1), 84-89 (1996
61. Mahmood I. Prediction of clearance and volume of distribution in the obese from normal weight subjects: An allometric approach. Clin Pharmacokinet. 51(8), 527-542 (2012
62. Mahmood I, Goteti K. Prediction of drug concentration-time data in humans from animals: A comparison of three methods. Xenobiotica; the fate of foreign Compounds in Biological Systems 42(8), 756-765 (2012
63. Oitate M, Nakayama S, Ito T, Kurihara A, Okudaira N, Izumi T. Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method. Drug Metab. Pharmacokinet. 27(3), 354-359 (2012
64. Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited. Biopharm. Drug Dispos. 31(4), 253-263 (2010
65. Mould DR, Sweeney KR: The pharmacokinetics and pharmacodynamics of monoclonal antibodies - mechanistic modeling applied to drug development. Curr. Opin. Drug Discov. Devel. 10(1), 84-96 (2007
66. Chen Y, Balthasar JP: Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. The AAPS J. 14(4), 850-859 (2012
67. Hansen RJ, Balthasar JP. Pharmacokinetic/ pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J. Pharm. Sci. 92(6), 1206-1215 (2003
68. Heiskanen T, Heiskanen T, Kairemo K. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody. Curr. Pharm. Design 15(9), 988-1007 (2009
69. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J. Pharmacokinetics Pharmacodynamics 39(1), 67-86 (2012
70. Thygesen P, Macheras P, Van Peer A. Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharmaceut. Res. 26(12), 2543-2550 (2009
71. Krzyzanski W, Sutjandra L, Perez-Ruixo JJ, Sloey B, Chow AT, Wang YM. Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals. Pharm. Res. 30(3), 655-669 (2013
72. Yang BB, Lum P, Chen A et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin. Pharmacokinetics 49(11), 729-740 (2010
73. Xiao JJ. Pharmacokinetic models for FcRn-mediated IgG disposition. J. Biomed. Biotechnol. 2012, 282989 (2012
74. Kuang B, King L, Wang H Therapeutic monoclonal antibody concentration monitoring: Free or total? Bioanalysis 2(6), 1125-1140 (2010
75. Lee JW, Kelley M, King LE et al. Bioanalytical approaches to quantify 'total' and 'free' therapeutic antibodies and their targets: Technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011
76. Burnette DT, Sengupta P, Dai Y, Lippincott- Schwartz J, Kachar B. Bleaching/blinking assisted localization microscopy for superresolution imaging using standard fluorescent molecules. Proc. Natl Acad. Sci. USA 108(52), 21081-21086 (2011
77. Dempsey GT, Vaughan JC, Chen KH, Bates M, Zhuang X. Evaluation of fluorophores for optimal performance in localization-based super-resolution imaging. Nat. Methods 8(12), 1027-1036 (2011
78. Li H, Ortiz R, Tran L et al. General LC-MS/ MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal. Chem. 84(3), 1267-1273 (2012
79. Li H, Ortiz R, Tran L et al. Simultaneous analysis of multiple monoclonal antibody biotherapeuticsby LC-MS/MS method in rat plasma following cassette-dosing. AAPS J. 14, (2012
80. Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1-2), 1-9 (2008
81. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. 5(2), 172-179 (2003
82. Ponce R. Preclinical support for combination therapy in the treatment of autoimmunity with atacicept. Toxicol. Pathol. 37(1), 89-99 (2009
83. Neubert H, Grace C, Rumpel K, James I. Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. Anal. Chem. 80(18), 6907-6914 (2008
84. Sickert D, Kroeger K, Zickler C et al. Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. J. Immunol. Methods 334(1-2), 29-36 (2008
85. Kelley M, Ahene A, Gorovits B et al. Theoretical considerations and practical approaches to address the effect of antidrug antibody (ADA) on quantification of biotherapeutics in circulation. AAPS J. (2013
86. Girish S, Martin SW, Peterson MC et al. AAPS workshop report: Strategies to address therapeutic protein-drug interactions during clinical development. AAPS J. 13(3), 405-416 (2011
87. Seitz K, Zhou H: Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: Reality check. J. Clin. Pharmacol. 47(9), 1104-1118 (2007
88. Huang SM, Zhao H, Lee JI et al. Therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Therap. 87(4), 497-503 (2010
89. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Therap. 85(4), 434-438 (2009
90. Vee ML, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab. Dispos. 37(3), 685-693 (2009
91. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin. Pharmacol. Therap. 89(5), 735-740 (2011
92. Delbaldo C, Pierga JY, Dieras V et al. Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur. J. Cancer 41(12), 1739-1745 (2005
93. Weisman MH, Moreland LW, Furst DE et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clin. Ther. 25(6), 1700-1721 (2003
94. Ganjoo KN, An CS, Robertson MJ et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leukemia Lymphoma 47(6), 998-1005 (2006
95. Ashino T, Arima Y, Shioda S, Iwakura Y, Numazawa S, Yoshida T. Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver. Eur. J. Pharmacol. 558(1-3), 199-207 (2007
96. Dickmann LJ, Mcbride HJ, Patel SK, Miner K, Wienkers LC, Slatter JG. Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression. Biochem. Pharmacol. 83(12), 1682-1689 (2012
97. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: Initial look. J. Clin. Pharmacol. 49(12), 1382-1402 (2009
98. Huang SM, Rowland M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin. Pharmacol. Therap. 91(3), 542-549 (2012
99. Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov. Today 14(17-18), 891-898 (2009